Samrat Pharmachem Ltd. (BSE: 530125) is a Mumbai, Maharashtra-based company in the Pharmaceutical Intermediates industry. With a market capitalisation of ₹86 Cr, it ranks #3,399 by market cap among the 6,189 Indian listed companies on FinBizNet, and #2 of 4 in Pharmaceutical Intermediates. At ₹277.50 (as of 26 Oct 2026), the share price is 10.4% below its 52-week high of ₹309.85 and 46.1% above its 52-week low of ₹190.00. The share price is down 4.1% over one year and up 10.6% over three months.
| Current Price | ₹277.50 |
|---|---|
| Market Cap | ₹86 Cr |
| BSE Code | 530125 |
| Sector | Materials > Chemicals > Speciality Chemicals |
| Sub-Industry | Specialty Chemicals > Pharmaceutical Intermediates |
| P/E Ratio | -25.9 |
| Return on Equity | -4.73% |
| Return on Assets | -1.41% |
| 52-Week Range | ₹190.00 – ₹309.85 |
| 1-Year Price Change | -4.1% |
| 3-Month Price Change | +10.6% |
| Beta (1Y) | 0.05 |
| Dividend Yield | 0.00% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.samratpharmachem.com |
| Revenue | ₹80 Cr |
|---|---|
| Net Profit | ₹1 Cr |
| Net Margin | 1.1% |
| EPS (Basic) | ₹2.84 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Samrat Pharmachem Limited engages in the manufacture and sale of pharmaceutical chemicals in India. It offers 3-5-di iodosalicylic acid, ammonium iodide, cadmium iodide, calcium iodate, clioquinol, copper iodide, ethyl iodide, ethylenediamine dihydroiodide, hydroiodic acid, iodine, iodine monochloride, iodoquinol, methyl iodide, n-iodo succinimide, periodic acid, potassium iodate and iodide, potassium metaper iodate, povidone iodine, sodium iodate and iodide, and sodium metaper iodate. The company serves the agrochemical, animal feed, chemical, cosmetics, food, pharmaceutical, printing, and textile industries. It also exports its products to the United States, Europe, Africa, Asia, the Middle East, and internationally. Samrat Pharmachem Limited was incorporated in 1992 and is based in Mumbai, India.
1. Manufactures Phamaceutical Chemicals-This segment manufactures and sells pharmaceutical chemicals. It offers iodine salts and bromines salts, as well as iodine derivatives for industries, such as pharmaceuticals, chemicals, food, fertilizers, salt, etc.
1. Pharmaceutical Chemicals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| DCM Shriram Fine Chemicals Limited | ₹215 Cr | -60.6 | -1.67% | ₹91 Cr | — |
| Samrat Pharmachem Ltd. | ₹86 Cr | -25.9 | -4.73% | ₹80 Cr | -4.1% |
| Eiko Lifesciences Ltd | ₹73 Cr | 15.9 | 8.40% | — | +0.6% |
| Caprolactam Chemicals Ltd. | ₹21 Cr | 12 | 30.87% | ₹0 Cr | +12.3% |
Listed by market capitalisation. Ratios are shown for context only.
Samrat Pharmachem Ltd. is trading at ₹277.50, with a market capitalisation of ₹86 Cr.
Samrat Pharmachem Ltd. operates in the Materials > Chemicals > Speciality Chemicals space (Specialty Chemicals > Pharmaceutical Intermediates).
Samrat Pharmachem Ltd. has a P/E of -25.9 and a return on equity of -4.73%.
Samrat Pharmachem Ltd. is listed on the BSE under the scrip code 530125.
Samrat Pharmachem Ltd.'s share price is down 4.1% over one year and up 10.6% over three months. Its 52-week range is ₹190.00 to ₹309.85.
In Q1 FY27, Samrat Pharmachem Ltd. reported revenue of ₹80 Cr and net profit of ₹1 Cr, with basic EPS of ₹2.84 (standalone, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.